Hong Kong Stock Connect | JD Health (06618) opens more than 3% higher after earnings, annual attributable profit up 29.16% year-on-year, "medical testing, diagnosis, and pharmaceuticals" closed-loop further improved

Reuters Finance APP reports that JD Health (06618) opened more than 3% higher after earnings release. As of the latest update, it rose 3.58% to HKD 49.2, with a trading volume of HKD 17.0767 million.

In terms of news, on March 5, JD Health announced its annual results for the year ending December 31, 2025. The group achieved revenue of 73.441 billion RMB, a 26.3% increase year-over-year; net profit attributable to shareholders was 5.375 billion RMB, up 29.16% year-over-year; basic earnings per share were 1.7 RMB. During the reporting period, JD Health further expanded its advantage as the “first stop for new drug launches online,” with over 100 new drugs launched throughout the year—significantly more than in 2024—demonstrating the company’s efficient pharmaceutical supply chain and professional service capabilities as core competitive advantages.

By 2025, JD Health will further improve the “medical-examination-prescription” service loop, continue to strengthen integrated online and offline healthcare services, and enhance specialized capabilities in dermatology, mental health, and chronic disease management through JD Internet Hospitals. JD Daojia’s rapid testing services have expanded to 27 cities nationwide, offering over 160 home testing services. Additionally, JD Health leverages AI technology to optimize intelligent consultation and health management products, improving service accuracy and accessibility, and building a professional, efficient full-scenario health service system.